Safety Study of HBV-002 West Nile Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
West Nile Virus Disease
Interventions
BIOLOGICAL

WN-80E

Three injections of the study vaccine \[Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)\] given one month apart

BIOLOGICAL

WN-80E

Three injections of the study vaccine \[Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)\] given one month apart

BIOLOGICAL

WN-80E

Three injections of the study vaccine \[High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)\] given one month apart

BIOLOGICAL

WN-80E

Three injections of the study vaccine \[High Dose WN-80E API (50 µg)\] given one month apart

Trial Locations (1)

96813

Covance Clinical Research Unit, Honolulu

Sponsors
All Listed Sponsors
lead

Hawaii Biotech, Inc.

INDUSTRY